Health: Alternative Medicine News

Today is March 19, 2024. All times in Eastern Daylight Time.

AMWC 2024: Galderma to Share New Data From Its Leading Injectable Aesthetic Portfolio

03/19/2024 - 02:00 AM

BUSINESS WIRE
Immunis Chairman Dr. Hans Keirstead to Present Abundance360 Moonshot

03/18/2024 - 03:32 PM

BUSINESS WIRE
CBD Healthcare Company Becomes the First-Ever Worldwide to Earn Prestigious NSF International Certifications in Personal Care for Athletes (NSF Guideline 527 and NSF Certified for Sport)

03/15/2024 - 12:53 PM

BUSINESS WIRE
Calling All Cannabis Enthusiasts! Cookies Baltimore Celebrates St. Patrick’s Day Weekend with the Inaugural COOKIES DAZE Celebration in Federal Hill

03/15/2024 - 10:15 AM

BUSINESS WIRE
Anthem Blue Cross and Blue Shield Foundation Awards $11 Million to Community Partners in New York

03/15/2024 - 10:00 AM

BUSINESS WIRE
Společnost Curaleaf International expanduje do České republiky díky partnerství se společností Astrasana Pharma

03/15/2024 - 09:57 AM

BUSINESS WIRE
Innovative Industrial Properties Declares First Quarter 2024 Dividends

03/15/2024 - 07:00 AM

BUSINESS WIRE
Cybin berichtet über ein positives Treffen mit der FDA zum Ende der Phase 2 für CYB003 bei schweren depressiven Störungen und über die Planung eines Programms der Phase 3

03/14/2024 - 05:48 PM

BUSINESS WIRE
Cybin annonce une réunion positive avec la FDA à la fin de la phase 2 pour le CYB003 dans le trouble dépressif majeur et la conception du programme de phase 3

03/14/2024 - 04:28 PM

BUSINESS WIRE
Cybin anuncia una reunión positivo de fin de fase 2 con la FDA para el uso de CYB003 en el trastorno depresivo mayor, así como el diseño del programa de fase 3

03/14/2024 - 02:25 PM

BUSINESS WIRE
Cybin kondigt positieve vergadering aan het einde van Fase 2 met FDA aan voor CYB003 bij depressieve stoornissen en het programmaontwerp voor Fase 3

03/14/2024 - 02:25 PM

BUSINESS WIRE
Cybin annuncia l’esito positivo di una riunione con la FDA sul termine della fase 2 riguardante CYB003 per il trattamento del disturbo depressivo maggiore e il progetto del programma di fase 3

03/14/2024 - 01:58 PM

BUSINESS WIRE
Devonian Announces Closing of a Private Placement of Units

03/14/2024 - 08:45 AM

BUSINESS WIRE
Devonian annonce la clôture d’un placement privé d’unités

03/14/2024 - 08:45 AM

BUSINESS WIRE
Curaleaf International Expands into Czech Republic with Astrasana Pharma Partnership

03/14/2024 - 07:30 AM

BUSINESS WIRE
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design

03/14/2024 - 07:30 AM

BUSINESS WIRE
Mannatech Announces Retirement of Alfredo Bala and Promotion of Landen Fredrick to President and CEO

03/13/2024 - 07:30 PM

BUSINESS WIRE
Cybin reçoit la désignation de thérapie innovante de la FDA pour sa molécule psychédélique CYB003 et annonce des données de durabilité positives à quatre mois pour le traitement du trouble dépressif majeur

03/13/2024 - 06:47 PM

BUSINESS WIRE
Annonce d’un placement privé sursouscrit de 150 millions USD

03/13/2024 - 05:25 PM

BUSINESS WIRE
Jamieson Wellness Inc. Reports Strong Fourth Quarter and Full Year 2023 Results

03/13/2024 - 04:05 PM

BUSINESS WIRE
Resumen: Cybin recibe la designación de terapia innovadora de la FDA para su nueva molécula psicodélica CYB003 y anuncia resultados positivos durante cuatro meses en el trastorno depresivo mayor

03/13/2024 - 02:22 PM

BUSINESS WIRE
Samenvatting: Cybin ontvangt FDA-aanduiding voor baanbrekende therapie voor zijn nieuwe psychedelische molecuul CYB003 en kondigt positieve duurzaamheidsgegevens over vier maanden aan voor depressieve stoornis

03/13/2024 - 02:22 PM

BUSINESS WIRE
Riassunto: Cybin riceve dalla FDA la designazione di terapia innovativa Breakthrough Therapy per la sua nuova molecola psichedelica CYB003 e annuncia dati positivi a quattro mesi per il disturbo depressivo maggiore

03/13/2024 - 02:22 PM

BUSINESS WIRE
Cybin erhält von der FDA den Status eines Therapiedurchbruchs für sein neuartiges psychedelisches Molekül CYB003 und gibt positive Daten zur viermonatigen Dauerhaftigkeit bei schwerer depressiver Störung bekannt

03/13/2024 - 02:22 PM

BUSINESS WIRE
Ankündigung einer überzeichneten Privatplatzierung von 150 Millionen US-Dollar

03/13/2024 - 01:57 PM

BUSINESS WIRE

1 2 3

Next »

Search